Tacrine treatment at high dose suppresses the recognition memory in juvenile and adult mice with attention to hepatotoxicity

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 6, 2011, Pages 421-427

  Pan, Si Yuan ^a   Guo, Bao Feng ^a   Zhang, Yi ^a   Yu, Qing ^a   Yu, Zhi Ling ^b   Dong, Hang ^a,b   Ye, Yan ^b   Han, Yi Fan ^c   Ko, Kam Ming ^d  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; TACRINE;

ADOLESCENT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC STIMULATION; CONTROLLED STUDY; DEFECATION; GROOMING; LIVER TOXICITY; LOCOMOTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; REARING; RECALL; RECOGNITION;

MUS;

EID: 79955979973     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00677.x     Document Type: Article

References (40)

1. Ishrat T, Parveen K, Khan MM, Khuwaja G, Khan MB, Yousuf S et al. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 2009;1281:117-27.
2. Watanabe T, Yamagata N, Takasaki K, Sano K, Hayakawa K, Katsurabayashi S et al. Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res 2009;1249:222-8.
3. Sellal F, Nieoullon A, Michel G, Michel BF, Lacomblez L, Geerts H et al. Pharmacology of Alzheimer's disease: where do we go from here? Therapie 2005;60:89-107 (in French).
4. Miller LJ. The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease. Consult Pharm 2007;22:754-62.
5. Amenta F, Tayebatti SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr Med Chem 2008;15:48-98.
6. Schildein S, Huston JP, Schwarting RK. Injections of tacrine and scopolamine into the nucleus accumbens: opposing effects of immediate vs delayed posttrial treatment on memory of an open field. Neurobiol Learn Mem 2000;73:21-30.
7. Schildein S, Huston JP, Schwarting RK. Open field habituation learning is improved by nicotine and attenuated by mecamylamine administered posttrial into the nucleus accumbens. Neurobiol Learn Mem 2002;77:277-90.
8. Sabolek HR, Bunce JG, Chrobak JJ. Intraseptal tacrine-induced disruptions of spatial memory performance. Behav Brain Res 2005;158:1-7.
9. Pan SY, Han YF, Yu ZL, Yang R, Dong H, Ko KM. Evaluation of acute tacrine treatment on passive-avoidance response, open-field behavior, and toxicity in 17- and 30-day-old mice. Pharmacol Biochem Behav 2006;85:50-6.
10. Barichello T, Martins MR, Reinke A, Feier G, Ritter C, Quevedo J et al. Cognitive impairment in sepsis survivors from cecal ligation and perforation. Crit Care Med 2005;33:221-3.
11. Comim CM, Pereira JG, Steckert A, Petronilho F, Barichello T, Quevedo J et al. Rivastigmine reverses habituation memory impairment observed in sepsis survivor rats. Shock 2009;32:270-1.
12. Detrait ER, Hanon E, Dardenne B, Lamberty Y. The inhibitory avoidance test optimized for discovery of cognitive enhancers. Behav Res Methods 2009;41:805-11.
13. Pan SY, Han YF. Learning deficits induced by 4 belladonna alkaloids are preferentially attenuated by tacrine. Acta Pharmacol Sin 2000;21:124-30.
14. Carriero DL, Outslay G, Mayorga AJ, Aberman J, Gianutsos G, Salamone JD. Motor dysfunction produced by tacrine administration in rats. Pharmacol Biochem Behav 1997;58:851-8.
15. Mayorga AJ, Carriero DL, Cousins MS, Gianutsos G, Salamone JD. Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects. Pharmacol Biochem Behav 1997;56:273-9.
16. Cousins MS, Finn M, Trevitt J, Carriero DL, Conlan A, Salamone JD. The role of ventrolateral striatal acetylcholine in the production of tacrine-induced jaw movements. Pharmacol Biochem Behav 1999;62:439-47.
17. Arrieta JL, Artalejo FR. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing 1998;27:161-79.
18. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
19. Pan SY, Han YF, Carlier PR, Pang YP, Mak DH, Lam BY et al. Schisandrin B protects against tacrine- and bis(7)-tacrine-induced hepatotoxicity and enhances cognitive function in mice. Planta Med 2002;68:217-20.
20. Pan SY. Circadian effects of scopolamine on memory, exploratory behavior, and muscarinic receptors in mouse brain. Acta Pharmacol Sin 1992;13:323-6.
21. Kondratova AA, Dubrovsky YV, Antoch MP, Kondratov RV. Circadian clock proteins control adaptation to novel environment and memory formation. Aging (Albany NY) 2010;2:285-97.
22. Pan SY. Features of memory on novel situation and avoidance response: evidence from comparison between open-field behavior and step-through task. Acta Pharmacol Sin 1995;16:125-9.
23. Pan SY, Han YF, Xu QP, Liu MY, Ma HZ, Ding WJ et al. Belladonna alkaloids-induced behavioral changes and amnesia on open-field and step-through in 18-, 28-, and 38-day-old mice. Acta Pharmacol Sin 1998;19:112-6.
24. Pan SY, Han YF. Comparison of the inhibitory efficacy of four belladonna drugs on gastrointestinal movement and cognitive function in food-deprived mice. Pharmacology 2004;72:177-83.
25. Carey RJ, De Palma G, Damianopoulos E, Hopkins A, Shanahan A, Müller CP et al. Dopaminergic and serotonergic autoreceptor stimulation effects are equivalent and additive in the suppression of spontaneous and cocaine induced locomotor activity. Brain Res 2004;1019:134-43.
26. Mehta H, Haobam R, Usha R, Mohanakumar KP. Evidence for the involvement of central serotonergic mechanisms in cholinergic tremor induced by tacrine in Balb/c mice. Behav Brain Res 2005;163:227-36.
27. Haider S, Khaliq S, Haleem DJ. Enhanced serotonergic neurotransmission in the hippocampus following tryptophan administration improves learning acquisition and memory consolidation in rats. Pharmacol Rep 2007;59:53-7.
28. Salamone JD, Carlson BB, Rios C, Lentini E, Correa M, Wisniecki A et al. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behav Brain Res 2005;156:173-9.
29. Turiiski VI, Argirova MD, Krustev AD. Non-anticholinesterase, non-cholinergic effect of tacrine on gastrointestinal smooth muscle tissues of rat. Folia Med (Plovdiv) 2005;47:45-51.
30. Krustev AD, Argirova MD, Getova DP, Turiiski VI, Prissadova NA. Calcium-independent tacrine-induced relaxation of rat gastric corpus smooth muscles. Can J Physiol Pharmacol 2006;84:1133-8.
31. Jin K, Xie L, Mao XO, Greenberg DA. Alzheimer's disease drugs promote neurogenesis. Brain Res 2006;1085:183-8.
32. Akaike A, Takada-Takatori Y, Kume T, Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 2010;40:211-6.
33. Hamden K, Carreau S, Ellouz F, Masmoudi H, El FA. Protective effect of 17beta-estradiol on oxidative stress and liver dysfunction in aged male rats. J Physiol Biochem 2007;63:195-201.
34. Feng JF, Chen TM, Wen YA, Wang J, Tu ZG. Study of serum argininosuccinate lyase determination for diagnosis of liver diseases. J Clin Lab Anal 2008;22:220-7.
35. Stachlewitz RF, Arteel GE, Raleigh JA, Connor HD, Mason RP, Thurman RG. Development and characterization of a new model of tacrine-induced hepatotoxicity: role of the sympathetic nervous system and hypoxia-reoxygenation. J Pharmacol Exp Ther 1997;282:1591-9.
36. Ezoulin MJ, Dong CZ, Liu Z, Li J, Chen HZ, Heymans F et al. Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. Toxicol In Vitro 2006;20:824-31.
37. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995;28:449-57.
38. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005;97:125-34.
39. Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab 2008;9:332-5.
40. Nanfaro F, Cabrera R, Bazzocchini V, Laconi M, Yunes R. Pregnenolone sulfate infused in lateral septum of male rats impairs novel object recognition memory. Pharmacol Rep 2010;62:265-72.